Origami B(DE3) Competent Cells - Novagen

Genotype: F^-ompT hsdS_B(r_B^- m_B^-) gal dcm lacY1 ahpC (DE3) gor522::Tn10 trxB (Kan^R, Tet^R)

This product contains genetically modified organisms (GMO). Within the EU GMOs are regulated by Directives 2001/18/EC and 2009/41/EC of the European Parliament and of the Council and their national implementation in the member States respectively. This legislation obliges us to request certain information about you and the establishment where the GMOs are being handled. Click here for Enduser Declaration (EUD) Form.

Origami B host strains carry the same mutationsin trxB and gor as the original Origami strains,except that they are derived from a lacZY mutantof BL21 to enable precise control of expressionlevels by adjusting the concentration of IPTG.Thus the Origami B strains combine the desirablecharacteristics of BL21, Tuner, and Origamistrains in one strain background. The mutationsin trxB and gor are selectable on kanamycin andtetracycline, respectively; therefore, these strainscannot be used with plasmids that can onlyselected with kanamycin or tetracycline. Thesestrains also include the lon and ompT deficiencesof BL21, which increase protein stability.

DE3 indicates that the host is a lysogen of λDE3, and therefore carries a chromosomal copy of the T7 RNA polymerase gene under control of the lacUV5 promoter. Such strains are suitable for production of protein from target genes cloned in pET vectors by induction with IPTG.

Origami B host strains carry the same mutations as the original Origami strain, except that they are derived from a lacZY mutant of BL21 to enable precise control of expression levels using IPTG.

0.4 ml1 mlComponent

•2 × 0.2 ml5 × 0.2 mlOrigami B(DE3) Competent Cells

•2 × 2 ml4 × 2 mlSOC Medium

•2 ng2 ngTest Plasmid

NOVAGEN is a registered trademark of Merck KGaA, Darmstadt, Germany

Toxicity: Multiple Toxicity Values, refer to MSDS (O)